Vanguard Group Inc Xenetic Biosciences, Inc. Transaction History

Vanguard Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.31 - $0.73 $19,108 - $44,997	-61,641 Reduced 38.86%	96,982 $39,000
Q4 2022 Feb 10, 2023	SELL	$0.27 - $5.75 $123,617 - $2.63 Million	-457,844 Reduced 74.27%	158,623 $46,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.08 $655,942 - $1.07 Million	516,490 Added 516.61%	616,467 $795,000
Q3 2021 Nov 12, 2021	BUY	$1.73 - $5.3 $16,007 - $49,040	9,253 Added 10.2%	99,977 $205,000
Q2 2021 Aug 13, 2021	BUY	$1.57 - $2.45 $142,436 - $222,273	90,724 New	90,724 $185,000

Ticker XBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,166,600
Market Cap $59.6M
Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-base...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.